Zhejiang Hisun Biomaterials Co.Ltd. (SHA:688203)
China · Delayed Price · Currency is CNY 14.63
-0.31 (-2.08%)
Sep 10, 2026, 4:00 PM EDT
SHA:688203 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,047 | 845.94 | 834.82 | 742.37 | 597.82 | 579.85 |
Other Revenue | 2.7 | 5.75 | 10.37 | 10.95 | 7.61 | 5.16 |
| 1,050 | 851.69 | 845.19 | 753.32 | 605.43 | 585.01 | |
Revenue Growth | 27.64% | 0.77% | 12.20% | 24.43% | 3.49% | 122.72% |
Cost of Revenue | 921.73 | 761.15 | 742.9 | 654.69 | 524.55 | 497.26 |
Gross Profit | 128.08 | 90.54 | 102.29 | 98.62 | 80.89 | 87.74 |
Selling, General & Admin | 40.78 | 37.74 | 31.73 | 32.36 | 30.34 | 25.53 |
Research & Development | 34.28 | 29.59 | 27.27 | 25.89 | 19.03 | 14.16 |
Other Operating Expenses | 8.24 | 6.51 | 4.8 | 3.38 | 4.76 | 2.87 |
Operating Expenses | 83.16 | 73.52 | 65.32 | 62.52 | 54.45 | 42.52 |
Operating Income | 44.93 | 17.03 | 36.97 | 36.11 | 26.43 | 45.22 |
Interest Expense | -2.89 | -6.08 | -7.59 | -7.48 | -9.63 | -10.76 |
Interest & Investment Income | 3.77 | 6.2 | 12.28 | 20.18 | 10.65 | 3.64 |
Currency Exchange Gain (Loss) | -0.29 | -0 | 2.12 | 1.78 | 7.93 | -1.34 |
Other Non Operating Income (Expenses) | -6.11 | -0.29 | -0.13 | -0.12 | -0.66 | -0.06 |
EBT Excluding Unusual Items | 39.42 | 16.85 | 43.64 | 50.45 | 34.72 | 36.71 |
Gain (Loss) on Sale of Investments | 0 | - | -0.06 | - | -1.77 | 0.18 |
Gain (Loss) on Sale of Assets | -0.82 | -0.82 | -0.51 | -0.97 | 5.12 | -0.72 |
Asset Writedown | -1.53 | -1.31 | - | - | - | - |
Other Unusual Items | 1.8 | 2.93 | 4.12 | 3.81 | 14.51 | 2.17 |
Pretax Income | 38.86 | 17.64 | 47.19 | 53.29 | 52.58 | 38.34 |
Income Tax Expense | 11.25 | 7.77 | 11.68 | 9.76 | 5.55 | 3.1 |
Earnings From Continuing Operations | 27.61 | 9.87 | 35.5 | 43.54 | 47.02 | 35.24 |
Minority Interest in Earnings | - | - | - | 0.01 | 0.01 | 0.03 |
Net Income | 27.61 | 9.87 | 35.5 | 43.55 | 47.04 | 35.27 |
Net Income to Common | 27.61 | 9.87 | 35.5 | 43.55 | 47.04 | 35.27 |
Net Income Growth | 103.19% | -72.21% | -18.47% | -7.41% | 33.34% | 16.12% |
Shares Outstanding (Basic) | 205 | 201 | 197 | 207 | 168 | 153 |
Shares Outstanding (Diluted) | 205 | 201 | 197 | 207 | 168 | 153 |
Shares Change | 6.04% | 2.02% | -4.88% | 23.45% | 9.53% | 66.61% |
EPS (Basic) | 0.13 | 0.05 | 0.18 | 0.21 | 0.28 | 0.23 |
EPS (Diluted) | 0.13 | 0.05 | 0.18 | 0.21 | 0.28 | 0.23 |
EPS Growth | 87.10% | -72.76% | -14.29% | -25.00% | 21.74% | -30.30% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -54.49 | -106.32 | -254.34 | -51.08 | -89.13 | -238.26 |
Free Cash Flow Per Share | -0.27 | -0.53 | -1.29 | -0.25 | -0.53 | -1.55 |
Dividend Per Share | - | - | 0.060 | 0.080 | 0.070 | - |
Dividend Growth | - | - | -24.94% | 14.29% | - | - |
Gross Margin | 12.20% | 10.63% | 12.10% | 13.09% | 13.36% | 15.00% |
Operating Margin | 4.28% | 2.00% | 4.37% | 4.79% | 4.37% | 7.73% |
Profit Margin | 2.63% | 1.16% | 4.20% | 5.78% | 7.77% | 6.03% |
Free Cash Flow Margin | -5.19% | -12.48% | -30.09% | -6.78% | -14.72% | -40.73% |
EBITDA | 127.35 | 86.27 | 102.47 | 89.71 | 68.3 | 81.62 |
EBITDA Margin | 12.13% | 10.13% | 12.12% | 11.91% | 11.28% | 13.95% |
D&A For EBITDA | 82.42 | 69.24 | 65.5 | 53.6 | 41.87 | 36.4 |
EBIT | 44.93 | 17.03 | 36.97 | 36.11 | 26.43 | 45.22 |
EBIT Margin | 4.28% | 2.00% | 4.37% | 4.79% | 4.37% | 7.73% |
Effective Tax Rate | 28.96% | 44.07% | 24.76% | 18.31% | 10.57% | 8.08% |
Revenue as Reported | 443.49 | 851.69 | 845.19 | 753.32 | 605.43 | 585.01 |